Figures have even estimated that biosimilars might be able to save the global healthcare industry around USD 160 BN between 2019 and 2023.
However, as things stand, biosimilars are not having as widespread an impact as possible. This article examines why, digging into three key analytical challenges that are thus far inhibiting Biosimilars production across the world.
Learn More About the Author
Luc-Alain Savoy, Global Head of Biologics at SGS, who has recently been added to the list of top 100 most influential people in the biopharmaceutical industry, has been working for SGS for over 32 years.
For more information, please contact:
Global Head of Marketing
t: +41 22 739 91 11